Insight Molecular Diagnostics Inc., which transitioned from its former name OncoCyte Corporation in June 2025, functions as a specialized diagnostics enterprise with operations extending across the United States and internationally. The company's core activities involve pioneering and marketing a diverse array of diagnostic solutions, including laboratory developed tests, kitted products intended solely for research, and comprehensive kitted clinical tests. Its developmental pipeline features advanced tools such as DetermaCNI, a blood-based monitoring system engineered to identify early cancer progression promptly after just one treatment cycle.